COMMON MAPS
Map version new-york activity top-down
Main site Contact
Menu
↑ parent activity group ·
research dossier

BREAKTHROUGH T1D
NEW YORK, NY · EIN 231907729 · Form 990 · FY2024 · NTEE G800 · Voluntary Health Associations · Very Large (>$50M) · breakthrought1d.org
revenue
$301.7M
expenses
$281.0M
net assets
$350.6M
employees
688
volunteers
235,000
program ratio
75%
mission · from form 990

IMPROVING LIVES BY ACCELERATING BREAKTHROUGHS TO CURE, PREVENT AND TREAT T1D. SEE SCHEDULE O.

profile · synthesized from sources

Breakthrough T1D is a nonprofit organization dedicated to accelerating research to cure, prevent, and treat type 1 diabetes (T1D). Founded in 1970 by parents of children with T1D, it funds scientific research, advocates for federal funding, and supports the development of life-changing therapies such as artificial pancreas systems and disease-modifying treatments. The organization also promotes early detection and public awareness to improve outcomes for those affected by T1D.

irs program accomplishments · form 990 part iii · fy2024

What they reported doing

  1. #1 primary $59.33M
    PUBLIC EDUCATION -- BREAKTHROUGH T1D (FORMERLY JDRF) EDUCATES THE COMMUNITY ABOUT TYPE 1 DIABETES (T1D) AND ITS COMPLICATIONS AND PROVIDES SUPPORT SERVICES AND RESOURCES TO DIAGNOSED CHILDREN AND ADULTS, THEIR FAMILIES, AND OTHERS. FOR AN EXPANDED DESCRIPTION OF PROGRAM SERVICE ACTIVITIES RELATED TO PUBLIC EDUCATION AND OUTREACH, SEE SCHEDULE O.
  2. #2 $29.46M
    RESEARCH SUPPORT -- BREAKTHROUGH T1D (FORMERLY JDRF) MAINTAINS AN IN-HOUSE TEAM OF SKILLED SCIENTIFIC, MEDICAL, POLICY, AND GOVERNMENT RELATIONS PROFESSIONALS WHO PLAY A CRITICAL ROLE IN LEADING AND SUPPORTING THE EVALUATION OF RESEARCH FUNDING OPPORTUNITIES BY BREAKTHROUGH T1D AND INFLUENCING RESEARCH DIRECTION AND THE DISBURSEMENT OF RESEARCH FUNDS FROM OTHERS. THESE PROFESSIONALS ALSO WORK WITH REGULATORY AND POLICY OFFICIALS TO ENSURE THAT RESEARCH CAN PROCEED WITHOUT DELAY AND RESULTS ARE UNDERSTOOD BY HEALTHCARE DECISION MAKERS. FOR AN EXPANDED DESCRIPTION OF PROGRAM SERVICE ACTIVITIES RELATED TO RESEARCH SUPPORT, SEE SCHEDULE O.
named programs · 5 · from sources

What they call their work

Artificial Pancreas Consortium
Launched in 2006, this initiative brings together public, private, and academic scientists to accelerate the development and delivery of artificial pancreas systems.
Children's Congress
First held in 1999, this biennial event empowers children with T1D to advocate for federal research funding by sharing their stories with Members of Congress.
Project ACT
Launched in 2024, Project ACT is a coordinated initiative to accelerate cell therapy products as cures for T1D by advancing research, regulatory pathways, access, and adoption.
T1D Index
Launched in 2022, the T1D Index provides the first comprehensive global data on type 1 diabetes, informing strategies to accelerate cures and improve care.
nPOD (Network for Pancreatic Organ Donors with Diabetes)
Established in 2007, nPOD is the world’s only tissue bank for donor pancreases and related tissues from people with or at risk for T1D, advancing research into the disease.
activities · 10 groups

What they do

  • Diabetes and Kidney Disease Research Funding 2 activities
    • Development of Clinical Guidance and Regulatory Frameworks
      Spearheaded the creation of the first internationally agreed-upon clinical guidance for monitoring individuals with T1D autoantibodies and helped establish a regulatory framework with the FDA for the approval of the first artificial pancreas system.
    • Facilitation of Research Collaboration and Innovation
      Launched the Artificial Pancreas Consortium to accelerate artificial pancreas development through public-private-academic collaboration and established the T1D Fund, the world’s first venture philanthropy fund for T1D, attracting over $800 million in private capital.
  • Disease-Specific Clinical & Patient Education 2 activities
    • Production and Distribution of Introductory and Clinical Trial Information
      Produces and distributes the Begin With Hope Guide as an introductory resource for managing life with type 1 diabetes and provides information about clinical trials to individuals within the first 100 days of diagnosis.
    • Support for Early Detection and Screening Programs
      Provides a screening decision tool, screening support guide, and access to free research-based early detection programs including TrialNet and ASK (Autoimmunity Screening for Kids). Operates "Ask the Experts" to connect individuals with healthcare professionals for early detection planning and confirmatory testing.
  • Biomedical Research and Innovation 1 activity
    • Development of Global Data and Research Infrastructure
      Launched the T1D Index, the first comprehensive global data initiative documenting type 1 diabetes prevalence in every country, and maintains nPOD, the world’s only tissue bank for pancreases from people with or at risk for T1D. Also advances global screening through Breakthrough T1D Early Detection.
  • Therapeutic Comfort Kits and Room Makeovers 1 activity
    • Distribution of Care Packs for Newly Diagnosed Individuals
      Distributes free Bags of Hope, Teen Packs, and Adult Packs containing Rufus the Bear with Diabetes, educational materials, and support resources to children, adolescents, and adults newly diagnosed with type 1 diabetes and their caregivers. These packs are provided through partnerships with hospitals, clinics, and doctor’s offices.
  • Organizational Governance & Leadership Development 1 activity
    • Internal Organizational Capacity Building
      Engages over 1,000,000 volunteers in the U.S., involves 145+ national and global board and committee members, and supports 1,600+ chapter-level board and sustaining board members. Operates a Culture & Belonging Council to advance equity, inclusion, and belonging within the organization.
  • Community Health Equity Initiatives 1 activity
    • International Access to Diabetes Supplies and Diagnosis Improvement
      Funds projects to improve type 1 diabetes diagnosis in low-income African countries, partners with the NCDI Poverty Network to provide glucometers and test strips (e.g., in Mozambique), and collaborates with local leaders in India to increase access to affordable insulin and test strips.
  • Diabetes Self-Management & Prevention Programs 1 activity
    • Provision of Educational Resources and Support for Type 1 Diabetes Management
      Provides comprehensive educational resources on blood sugar monitoring, insulin administration, carbohydrate counting, nutrition, physical activity, mental health, and diabetes technologies such as CGMs and automated insulin delivery systems. Also offers guidance for caregivers and peer support connections globally.
  • Pharmacy Access and Medication Assistance 1 activity
    • Support for Affordable Insulin Access
      Supported Civica’s initiative to produce affordable biosimilar insulins available at no more than $30 per vial or $55 per box of five pens, regardless of insurance status.
  • Medical Research & Education Dissemination 1 activity
    • Support for Clinical Implementation and Knowledge Sharing
      Develops and provides slide presentations for grand rounds, partners with clinical practices nationwide to implement best practices for T1D screening, and facilitates sharing of clinical workflows, EHR templates, and change packages developed by T1D Exchange.
  • Uncategorized 3 activities
    • Advocacy for Policy Change and Access to Diabetes Technologies
      Advocates for insurance coverage of insulin pumps and CGMs in the U.S. and affiliated countries; contributed to NHS pilot rollout of artificial pancreas technology in England and secured access to CGMs for all pregnant women with T1D in England and Wales. Advocacy efforts led to over half a billion dollars in new T1D investment in Australia.
    • Delivery of Continuing Education for Healthcare Professionals
      Offers accredited on-demand courses and live webinars for healthcare professionals on emerging therapies in type 1 diabetes, providing CME/CEU credit. Topics include early-stage care and ongoing clinical trials.
    • Funding and Advancement of Type 1 Diabetes Research
      Invests in over 500 active T1D therapy research projects globally, including more than 50 in Australia and 67 in Canada (with $66 million CDN in multi-year grants). Has funded breakthroughs including the HbA1c test, Humulin, CGM efficacy trials, teplizumab (Tzield™), Lantidra™, and stem-cell-derived beta cell therapies. Invested over $266 million in disease-modifying therapies, screening, and closed-loop delivery systems.
financials · form 990 · fy2024
revenue
Total revenue$301.72M
Contributions & grants$277.04M92%
Program service revenue$00%
Investment income$13.79M5%
Other revenue$10.89M
expenses
Total expenses$281.01M
Program expenses75%
Admin / overhead7%
Fundraising18%
Salaries & benefits$93.00M
Grants paid out$121.75M
Largest expense lineCompensation
balance sheet
Total assets$534.56M
Cash$13.76M
Investments$364.04M
Liabilities$183.98M
Net assets$350.58M
Liquid reserves16.1 mo
6 years on record · 2019–2024 · YoY revenue +16.9%
leadership · form 990 part vii · fy2024

Who runs it

paid leadership · 16
NameTitleHours/wkCompensation
AARON KOWALSKI CHIEF EXECUTIVE OFFICER 50 $1.05M
STEVEN ST PETER MANAGING DIR. T1D FUND (END 1/25) 50 $860K
HELEN ELLIAS FORMER KEY EMPLOYEE 0 $662K
ROBERT KING CFAO/TREASURER (END 1/25) 50 $581K
PAMELA MORRISROE CHIEF MARKETING OFFICER 50 $564K
KATHLEEN SEITZ CHIEF GLOBAL DEVELOPMENT OFFICER 50 $560K
LYNN STARR CHIEF GLOBAL ADVOCACY OFFICER 50 $505K
SANJOY DUTTA PHD CHIEF SCIENTIFIC OFFICER 50 $480K
TRACY MIDO CHIEF HUMAN RESOURCES OFFICER 50 $423K
JESSE RABEN CHIEF LEGAL & RISK OFC, SECRETARY 50 $384K
HARDIK SANGHVI VP, ENTERPRISE ARCHITECTURE AND SE 50 $348K
SYDNEY YOVIC FORMER OFFICER 0 $332K
AMY MONTALTO VICE PRESIDENT, VOLUNTEER ENGAGEMENT 50 $310K
MARGARET MORRIS CFO, TREASURER (START 3/25) 50 $280K
JAMES MCDONALD FORMER OFFICER 0 $157K
ANNETTE FREYTAG CHIEF OF STAFF, TREAS (1/25-3/25) 50 $89K
board members · 9
  • CARLTON MCMILLAN — BOARD MEMBER
  • CHRISTOPHER TURNER — CHAIR, NOMINATING & GOV. COMM.
  • CLAUDIA GRAHAM PHD — BOARD MEMBER
  • DRAYTON VIRKLER — BOARD MEMBER
  • ELIZABETH CASWELL — CHAIR, TALENT & COMP. COMM.
  • JENNIFER SCHNEIDER MD — CHAIR, MISSION IMPACT COMM.
  • JOE LACHER JR — BOARD MEMBER
  • KAREN JORDAN — CHAIR, FINANCE & INVESTMENT COMMITTEE
  • KAREY L WITTY — BOARD MEMBER
relationships · 36

Who they work with

  • ASK (Autoimmunity Screening for Kids) Partner — Supports the ASK program, a free research-based initiative offering type 1 diabetes and celiac disease screening to individuals ages 1–99 in the U.S.
  • Aaron J. Kowalski Partner — CEO of Breakthrough T1D who has lived with type 1 diabetes for over 35 years and provides personal messages of support.
  • Abbott Partner — Corporate partner that advances research and innovation through significant mission-focused funding.
  • Australia Partner — Australia affiliate funding research and advocacy efforts for type 1 diabetes.
  • Australia Partner — International affiliate collaborating on therapy access and research.
  • Breakthrough T1D Children's Congress Network — Delegates from the Breakthrough T1D Children's Congress advocate on Capitol Hill to influence policy for type 1 diabetes.
  • British Society for Immunology Partner — Co-founded the Connect Immune Research initiative to study autoimmune conditions.
  • Canada Partner — Canada affiliate funding research, advocacy, and community engagement for type 1 diabetes.
  • Canada Partner — International affiliate collaborating on therapy access and research.
  • Canadian Institutes of Health Research (CIHR) Partner — Co-funded a clinical trial on continuous glucose monitoring in pregnant women with type 1 diabetes.
  • Capitol Hill Government — Organiza eventos de defensa legislativa en Capitol Hill con familias afectadas por diabetes tipo 1.
  • Civica Partner — Nonprofit pharmaceutical manufacturer supported in producing affordable biosimilar insulins.
  • Ford Motor Company Partner — Corporate partner whose employees volunteer with Breakthrough T1D through global action and engagement activities.
  • Hy-Vee Partner — Corporate partner that drives customer engagement through retail fundraising and sponsors Walk events to support Breakthrough T1D.
  • International Diabetes Federation Partner — Collaborates with Breakthrough T1D to drive investments in T1D research and care.
  • Israel Partner — International affiliate collaborating on therapy access and research.
  • Israel Partner — Israel affiliate focused solely on type 1 diabetes research and advocacy.
  • Israel Science Foundation Partner — Partnered with Israel Science Foundation to establish a $6 million initiative for T1D research.
  • MS Society Partner — Co-founded the Connect Immune Research initiative to study autoimmune conditions.
  • Medtronic Partner — Industry partner in the development and commercialization of the first insulin pump and the first FDA-approved artificial pancreas system.
  • NCDI Poverty Network Partner — Partnered with Breakthrough T1D to provide a glucometer and test strips to a person with T1D in Mozambique.
  • National Health Service (NHS) Government — Collaborated with NHS on pilot rollout of artificial pancreas technology and provision of continuous glucose monitors.
  • Netherlands Partner — International affiliate collaborating on therapy access and research.
  • Netherlands Partner — Netherlands affiliate supporting scientific research in type 1 diabetes.
  • SanMar Partner — Corporate partner that mobilizes employees to participate, fundraise, and champion the mission of Breakthrough T1D.
  • T1D Exchange Partner — Collaborates with T1D Exchange to develop a change package for clinics implementing type 1 diabetes early detection, funded by Breakthrough T1D.
  • TrialNet Partner — Collaborates with TrialNet to provide free early detection screening and clinical trial access for individuals at risk of type 1 diabetes.
  • UNICEF Partner — Collaborates with Breakthrough T1D to drive investments in T1D research and care.
  • United Kingdom Partner — International affiliate collaborating on therapy access and research.
  • United Kingdom Partner — UK affiliate advancing research and advocacy for type 1 diabetes, including artificial pancreas technology rollout.
+ 6 more
strategies · 3

How they approach the work

Named approaches extracted from this org’s sources. Where others share an approach, follow it to see the full set of orgs running it.

  • Early Detection and Intervention as Preventive Pathway
    methodology: early_detection_for_prevention
    By detecting type 1 diabetes early, individuals can access therapies and clinical trials that delay insulin dependence and prevent life-threatening complications like DKA, because early biological intervention during pre-symptomatic stages changes disease trajectory and empowers informed decision-making.
  • Integrated Research-Advocacy-Community Model
    methodology: integrated_research_advocacy_community
    By combining research funding, policy advocacy, and community support, BREAKTHROUGH T1D accelerates therapy development and improves care access, because multi-pronged pressure across scientific, systemic, and lived-experience domains creates faster, more equitable progress toward cures and care.
  • Peer and Emotional Support as Resilience-Building Mechanism
    methodology: peer_support_network
    By connecting individuals with peers and providing emotional support tools (e.g., therapeutic companions), BREAKTHROUGH T1D reduces isolation and fear, especially post-diagnosis, because shared experience and emotional safety increase self-efficacy and long-term disease management resilience.